TRIAMTERENE AND HYDROCHLOROTHIAZIDE tablet

Pays: États-Unis

Langue: anglais

Source: NLM (National Library of Medicine)

Ingrédients actifs:

HYDROCHLOROTHIAZIDE (UNII: 0J48LPH2TH) (HYDROCHLOROTHIAZIDE - UNII:0J48LPH2TH), TRIAMTERENE (UNII: WS821Z52LQ) (TRIAMTERENE - UNII:WS821Z52LQ)

Disponible depuis:

DirectRX

DCI (Dénomination commune internationale):

TRIAMTERENE

Composition:

TRIAMTERENE 37.5 mg

Mode d'administration:

ORAL

Type d'ordonnance:

PRESCRIPTION DRUG

indications thérapeutiques:

This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone.Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arryhthmias, etc.). Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs, such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not pre

Statut de autorisation:

Abbreviated New Drug Application

Résumé des caractéristiques du produit

TRIAMTERENE AND HYDROCHLOROTHIAZIDE- TRIAMTERENE AND
HYDROCHLOROTHIAZIDE TABLET
DIRECTRX
----------
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
DESCRIPTION
Triamterene and hydrochlorothiazide combines triamterene, a
potassium-conserving
diuretic, with the natriuretic agent, hydrochlorothiazide.
Each Triamterene and Hydrochlorothiazide 37.5 mg/25 mg Tablet, USP
contains 37.5
mg of Triamterene, USP and 25 mg of Hydrochlorothiazide, USP.
Each Triamterene and Hydrochlorothiazide 75 mg/50 mg Tablet, USP
contains 75 mg
of Triamterene, USP and 50 mg of Hydrochlorothiazide, USP.
Triamterene and hydrochlorothiazide tablets for oral administration
contains the
following inactive ingredients: lactose monohydrate, magnesium
stearate,
microcrystalline cellulose, and sodium starch glycolate. In addition,
the 37.5 mg/25
mg tablets contain D&C Yellow No.10 Aluminum Lake and FD&C Blue No.1
Aluminum
Lake.
Triamterene is 2,4,7-triamino-6-phenylpteridine. Triamterene is
practically insoluble in
water, benzene, chloroform, ether and dilute alkali hydroxides. It is
soluble in formic
acid and sparingly soluble in methoxyethanol. Triamterene is very
slightly soluble in
acetic acid, alcohol and dilute mineral acids.
Hydrochlorothiazide is 6-chloro-3,4-dihydro-2H -1,2,4,
benzothiadiazine-7-
sulfonamide 1,1-dioxide. Hydrochlorothiazide is slightly soluble in
water and freely
soluble in sodium hydroxide solution, n-butylamine and
dimethylformamide. It is
sparingly soluble in methanol and insoluble in ether, chloroform and
dilute mineral
acids. Its molecular weight is 297.73.
CLINICAL PHARMACOLOGY
Triamterene and hydrochlorothiazide is a diuretic, antihypertensive
drug product,
principally due to its hydrochlorothiazide component; the triamterene
component
reduces the excessive potassium loss which may occur with
hydrochlorothiazide use.
Hydrochlorothiazide
Hydrochlorothiazide is a diuretic and antihypertensive agent. It
blocks the renal tubular
absorption of sodium and chloride ions. This natriuresis and diuresis
is accompanied by
a secondary loss